True erythrocytosis is not a cancer, but it is a neoplastic disease.
Cancer refers to malignant tumors originating from epithelial tissues, such as lung cancer originating from alveolar or bronchial epithelium, gastric cancer originating from gastric mucosal epithelium, pancreatic cancer originating from pancreatic ductal epithelium, breast cancer originating from breast ductal epithelium, and so on, whereas Erythropoietic dysgerminosis is an acquired clonal hematopoietic stem cell disease originating from hematopoietic stem cells, and thus does not belong to cancer.
Although not cancerous, Erythropoiesis belongs to the neoplastic disease caused by clonal proliferation of bone marrow cells, which is strictly a tumor. However, due to the relatively mature degree of cell differentiation, its clinical regression and prognosis are better than that of acute leukemia, lymphoma and other hematologic malignancies.
The main feature of Erythropoiesis is the increase of peripheral blood erythrocyte specific volume, which brings about problems such as increased blood viscosity, splenomegaly, and easy to form thrombus or hemorrhage, etc. Generally speaking, the survival period after active treatment can be up to 10-15 years, while individual patients may evolve into acute leukemia and shorten the survival period.
Patients with true erythrocytosis are advised to go to the hospital as soon as possible, and be treated accordingly under the guidance of professional doctors, with drugs such as hydroxyurea, etc., to slow down the progress of the disease as much as possible, and prevent complications from occurring, and most of the patients can have a longer survival period.